Points to Keep in Mind Before Subscribing to Krishna Institute of Medical Sciences' IPO - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  
  • Home
  • Views On News
  • Jun 15, 2021 - Points to Keep in Mind Before Subscribing to Krishna Institute of Medical Sciences' IPO

Points to Keep in Mind Before Subscribing to Krishna Institute of Medical Sciences' IPO

Jun 15, 2021

Krishna Institute of Medical Sciences (KIMS) is a Hyderabad-based company that operates multi-specialty hospitals in Telangana and Andhra Pradesh.

The company's Rs 21.4 bn initial public offering (IPO) will hit the street on 16 June, alongside Dodla Dairy.

The price band of the offer has been fixed between Rs 815 and Rs 825 per equity share.

Axis Capital, Kotak Mahindra Capital, Credit Suisse Securities, and IIFL Securities have been appointed as merchant bankers to advise the company on the IPO.

Link Intime India will be the registrar to Krishna Institute of Medical Sciences issue.

Krishna Institute of Medical Sciences IPO Details

Issue Type Book Built Issue IPO
Face Value Rs 10 per equity share
IPO Price Rs 815 to Rs 825 per equity share
Market Lot 1 lot - 18 shares
Issue Size Rs 21.4 bn
Fresh Issue Rs 2 bn
Offer for Sale Rs 19.4 bn
Basis of Allotment Date Wednesday, June 23, 2021
IPO Listing Date Monday, June 28, 2021
Data Source: Company's Red Herring Prospectus

Currently, the promoters hold 46.8% stake in the company, post issue the shareholding will come down to 38.8%.

The company's existing investors, US equity giant General Atlantic and the promoters, will offer 21.3 m shares totaling to Rs 19.4 bn.

Dr. Bhaskara Rao Bollineni, Rajyasri Bollineni, Dr. Abhinay Bollineni, Adwik Bollineni, and Bollineni Ramanaiah Memorial Hospitals Private Limited are the company promoters.

--- Advertisement ---
FREE Event on Equitymaster's New Project

On July 29 , we are holding a FREE event to reveal Equitymaster's Great Indian Wealth Project.

At this event, we'll reveal the details of your first stock for a potential Rs 7 crore in long-term wealth.

Seats for this event are filling up fast.

Since there are limited seats, we urge you to register at the earliest.

Click here for free sign-up

Shares on offer

Up to 75% (Rs 15.9 bn) portion of the net offer has been reserved for qualified institutional buyers (QIBs), 15% (Rs 3.2 bn) for non-institutional buyers (NIBs) and 10% (Rs 2.1 bn) for retail investors.

While equity shares worth Rs 200 m have been kept reserved for employees.

A discount of Rs 40 per share will be given to the eligible employees bidding in the employee reservation portion.

Using the bullish equity market to pare its debt

The IPO proceeds worth Rs 2 bn raised via fresh issue will go to the company.

Of this, it intends to repay Rs 1.5 bn worth borrowing.

The remaining Rs 500 m will go towards general corporate purposes, which can include capital expenditure, partnerships, among other things.

About Krishna Institute of Medical Sciences

Incorporated in 1973, Krishna Institute of Medical Sciences is one of the largest healthcare groups in Andhra Pradesh and Telangana.

KIMS provides multi-disciplinary healthcare services with a key focus on primary, secondary, and tertiary care in tier 2-3 cities.

The company offers a comprehensive range of healthcare services including oncology, cardiac sciences, neurosciences, gastric sciences, orthopedics, renal sciences, organ transplantation, and mother & child care.

As of 31 March 2021, it operates through 9 multi-specialty hospitals under the brand name of 'KIMS Hospitals' with an aggregate bed capacity of 3,064 including over 2,500 operational beds.

Free Signup: The Smallcap Revival Summit

Company's competitive strengths

  • One of the largest corporate healthcare service provider in south India.
  • Highly qualified and trained doctors and medical support staff.
  • Strong operational and financial performance.
  • Experienced managerial team.

Expansion plans get a shot in the arm

KIMS wants to ride the bull run in India's equity markets to expand its operations to adjacent areas like Karnataka, Odisha, Tamil Nadu, and even central India.

Among these, Bengaluru and Chennai could be the next big markets for KIMS.

Apart from this, the liquidity boost could help KIMS expand its bed capacity and healthcare equipment to augment its operations.

The financials

The company has posted growth in its top and bottom lines for the last three fiscals.

For the last three financial years, the company has (on a consolidated basis) posted an average earnings per share (EPS) of Rs 17.4.

The issue is priced at a P/BV (price to book value) of 7.2 based on its net asset value (NAV) of Rs 115.4 as of 31 March 2021.

Key Financial Indicators

(Rs m) FY18 FY19 FY20 Dec-20
Revenues 6,636.7 9,180.1 11,226.5 9,714.0
Revenue Growth (%)   38.3% 22.3%  
Expenses 7,213.9 9,389.1 9,882.0 7,793.8
Profit Before Tax (PBT) -204.5 -150.4 1,405.3 1,980.0
Net Profit -461.9 -485.9 1,150.7 1,468.6
Data Source: Company's Red Herring Prospectus

As per offer documents, KIMS has not paid any dividend in the last three fiscals but will follow a prudent dividend policy based on its financial performance, future prospects and the procedure framed for the same.

For more details, check out Krishna Institute of Medical Sciences Red Herring Prospectus.

--- Advertisement ---
Predict Stock's Next Move Using Volumes

Volumes play a key role in identifying emerging trends.

They help you track activities of big smart investors.

Watch this video to learn how to use volumes to identify trades with astonishing risk:reward profile.

Revenue concentration remains a key area of concern for KIMS

The hospital's two branches, namely KIMS Kondapur and KIMS Secunderabad - both located in Hyderabad, contribute nearly two-thirds to the total revenue of the company.

A high concentration of revenue could hamper the company's prospects if it cannot expand and diversify in a meaningful manner.

Covid-19 had a noticeable adverse impact on company's operations

Despite a surge in revenue and profit, KIMS says that the Covid-19 pandemic had an adverse impact on its operations.

The company says that in March 2020 and more so in April 2020, it witnessed a substantial decline in in-patient and out-patient volumes.

When compared to February 2020, its inpatient volumes fell by more than half in April 2020.

It also notes that some patients were reluctant to visit hospitals due to a perceived notion of increased risk of infection.

Heightened risk of its doctors, nurses and other healthcare workers, and a resulting increase in costs to ensure their safety also remains another area of concern for the company.

Comparison with listed peers

The peer group companies listed in India are Apollo Hospitals Enterprise, Fortis Healthcare, Narayana Hrudayalaya, and Max Healthcare Institute.

Comparative Analysis

Company Revenues Net Profit Return on Net Worth (%)
Apollo Hospitals 112.5 4.3 13.6%
Fortis Healthcare 46.3 0.8 0.9%
Narayana Hrudayalaya 31.3 1.2 10.5%
Max Healthcare 18.8 1.0 1.9%
Krishna Institute 11.2 1.2 16.8%
Data Source: RHP, Equitymaster
Figures in Rs bn and as on 31 March 2020

Grey market premium

The grey market, where investors seek the first cue on public issues, is sufficiently enthused too.

The unofficial market for trading in unlisted shares is signaling good response for most of the current IPO issues.

As of 15 June 2021, KIMS Hospital is commanding a grey market premium of Rs 150-160, signaling a 18-20% upside over the issue price.

According to analysts, the company's business model is attractive, but high pricing is a concern.

There is not much buzz about the issue. However, they expect it to be a positive surprise for investors.

What's the ideal IPO strategy to follow?

The excitement surrounding the slew of IPOs in the coming months is huge.

As many as four companies are coming out with their IPOs this week.

These include Shyam Metalics, Sona Comstar, Dodla Dairy, and Krishna Institute of Medical Sciences.

Investors are already euphoric on loss making companies such as Zomato and Paytm.

Smallcap analyst at Equitymaster, Richa Agarwal, recently shares her views on the much-hyped Paytm IPO.

Here's what she wrote...

  • Investing in a company is like owning a piece of business.

    A loss-making business with no clear road to profits isn't one I would recommend.

    And certainly not at the time of its IPO.

You can read the entire editorial here: Paytm IPO: Will it Deliver Profits?

If you are investing in an IPO, weigh in all the positive and negative factors affecting the company.

Take a close look at the company's financials and valuations. It would give you a clear picture of what's brewing.

Happy Investing!

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...

Equitymaster requests your view! Post a comment on "Points to Keep in Mind Before Subscribing to Krishna Institute of Medical Sciences' IPO". Click here!


More Views on News

CAPLIN POINT Share Price Up by 5%; BSE HEALTHCARE Index Up 0.1% (Market Updates)

Jul 23, 2021 | Updated on Jul 23, 2021

CAPLIN POINT share price is trading up by 5% and its current market price is Rs 788. The BSE HEALTHCARE is up by 0.1%. The top gainers in the BSE HEALTHCARE Index are CAPLIN POINT (up 5.2%) and SUN PHARMA ADV. RES. (up 7.4%). The top losers are FDC and JUBILANT PHARMOVA .

CAPLIN POINT at All Time High; BSE HEALTHCARE Index Up 0.1% (Market Updates)

Jul 23, 2021 | Updated on Jul 23, 2021

CAPLIN POINT share price has hit an all time high at Rs 796 (up 3.7%). The BSE HEALTHCARE Index is up by 0.1%. Among the top gainers in the BSE HEALTHCARE Index today are CAPLIN POINT (up 3.7%) and ABBOTT INDIA (up 1.3%). The top losers include LUPIN and THYROCARE TECHNOLOGIES (down 0.1%).

Bajaj Healthcare Rallies 11% on DRDO Nod to Manufacture Oral Covid Drug (Views On News)

Jul 8, 2021

Bajaj Healthcare has more than doubled investors' wealth in the year 2021 so far. The counter has delivered over 240% return in the last one year.

Why Did Pharma Stocks Surge? (Views On News)

Jul 17, 2021

A look into the factors contributing to the rally in pharma stocks.

Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary (Views On News)

Jul 2, 2021

Here's why the company sold its business unit to Eugia Pharma Specialities.

More Views on News

Most Popular

A Complete Guide for Beginners on How to Invest in IPOs

As an investor, you must have endeavoured to find a suitable opportunity for investing in IPOs. But do you know what is an IP...

A 25 Bagger Indian Stock at the Centre of the Global Semiconductor Chip Shortage (Profit Hunter)

Jul 13, 2021

One technology company in India is grossly underrated despite its dominant role in semiconductor chip designing.

RBI Opens a New Market for Investors (Fast Profits Daily)

Jul 16, 2021

You now have a new way to create wealth. Grab it with both hands.

OPEC is Dying! RIP OPEC (Fast Profits Daily)

Jul 13, 2021

Why the global oil cartel is unravelling and how India stands to gain.

Top 4 Companies that Are Strong Monopolies (Views On News)

Jul 10, 2021

A close look at the top 4 companies with a dominant position in their industry.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Jul 23, 2021 (Close)